#ESMO26 Dr. Li Zhang presents PANKU-Lung01: phase III izalontamab brengitecan (iza-bren, HER3:EGFR ADC) vs platinum based chemo in EGFR+ NSCLC after 3G TKI. Iza bren improved PFS:

Stephen V Liu, MD· @StephenVLiu · X·2026-10-26 16:27· 5 小时前评分70

正文 · 原文

#ESMO26 Dr. Li Zhang presents PANKU-Lung01: phase III izalontamab brengitecan (iza-bren, HER3:EGFR ADC) vs platinum based chemo in EGFR+ NSCLC after 3G TKI. Iza bren improved PFS: 11.1 vs 5.7m, HR 0.40! OS immature but 1y rates 83% vs 73%. High reduction/interruption rates but low discontinuation rates. Most common toxicities were hematologic in nature. Very exciting data here: ADCs here to stay. #ESMOAmbassadors

196 浏览 · 5 赞 · 3 转发 · 0 回复

会议摘要

2575PNCT06838273 NCT06838273 NCT06838273按 NSCLC, locally advanced 对上

Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)

https://esmocongress.esmo.org

LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上

PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

https://esmocongress.esmo.org

来源：Stephen V Liu, MD · x.com